Gold prices dip as hawkish Fed minutes weigh ahead of Jackson Hole
Phreesia, Inc. (NYSE:PHR), a $1.4 billion healthcare technology company, has reported that its Chief Financial Officer, Balaji Gandhi, sold shares worth approximately $191,895, according to a recent SEC filing. The transactions took place on April 8, 2025, and involved the sale of a total of 8,045 shares of common stock. According to InvestingPro data, the company maintains a "GREAT" financial health score and shows strong revenue growth of ~18% over the last twelve months.
The shares were sold in two separate transactions, with the first involving 4,916 shares at a weighted average price of $23.4568 per share, within a price range of $23.00 to $23.995. The second transaction involved 3,129 shares sold at a weighted average price of $24.475, with prices ranging from $24.00 to $24.915 per share. These sales were conducted as part of Phreesia's mandatory sell-to-cover policy to address tax withholding obligations related to the settlement of restricted stock units.
Following these transactions, Gandhi retains direct ownership of 108,411 shares in the company.
In other recent news, Phreesia Inc . has been the focus of several analyst reports following its latest earnings release. Jefferies raised its price target for Phreesia from $28.00 to $32.00, maintaining a Buy rating based on the company's fourth-quarter earnings and management's comments. The firm expressed confidence in Phreesia's growth prospects, emphasizing operational leverage and a strategic shift towards Network Solutions. KeyBanc Capital Markets also maintained an Overweight rating with a $30.00 target, highlighting strong margin improvements and top-line growth, particularly in the Network Solutions sector. KeyBanc's projections indicate continued revenue growth and margin expansion for the coming years. Meanwhile, Raymond (NSE:RYMD) James reiterated an Outperform rating with a $30.00 target, focusing on Phreesia's transition to a free cash flow-oriented strategy. The firm believes this strategic shift will enhance the conversion of earnings into cash flow. Lastly, DA Davidson reaffirmed a Buy rating with a $36.00 target, praising Phreesia's consistent performance and potential for profit improvement within the U.S. healthcare services sector. The firm considers Phreesia's current valuation to be undervalued compared to its peers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.